IGF-1 LR3 half-life & pharmacokinetics

Reported half-life

Approximately 20-30 hours plasma half-life, materially extended from native IGF-1's ~10-20 minute plasma half-life through reduced IGFBP binding. The N-terminal 13-amino-acid extension and Arg3 substitution both interfere with IGFBP-3 binding — the principal circulating carrier of IGF-1 — leaving more free bioactive peptide available for receptor engagement.

The half-life and pharmacokinetic profile of IGF-1 LR3 reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (research; standard route)
• Intramuscular injection (research; less common)
• Cell culture medium (in-vitro research; standard use)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Recombinant IGF-1 analogue engineered for extended plasma half-life through reduced IGF-binding-protein affinity; direct IGF-1 receptor agonist.

Mechanism context

Half-life interpretation depends on the underlying mechanism. IGF-1 LR3 acts as follows:

IGF-1 LR3 is a recombinant analogue of human insulin-like growth factor 1 (IGF-1) engineered specifically for cell-culture and research applications where extended half-life and reduced IGFBP interference are desirable. The native human IGF-1 protein comprises 70 amino acids arranged in a compact tertiary structure with three intrachain disulfide bonds; native IGF-1 has a plasma half-life of only 10-20 minutes because approximately 98% of circulating IGF-1 is bound to IGF-binding proteins (predominantly IGFBP-3 with the acid-labile subunit ALS), which sequesters IGF-1 from receptor engagement and constrains bioavailable free IGF-1 to a small fraction of total.

See the full IGF-1 LR3 research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.